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Abstract
This second section of the first ECCO pathogenesis workshop on anti-TNF therapy failures in
inflammatory bowel diseases addresses the biological roles of TNFα and the effects and
mechanisms of action of TNFα antagonists. Mechanisms underlying their failure, includingis factor alpha; tmTNF, transmembrane TNF; TACE, TNFα converting enzyme; sTNF, soluble TNF; TRAF,
-associated death domain; mAbs, monoclonal antibodies; IMID, immune-mediated inflammatory
X, Infliximab; ADA, Adalimumab; CZP, Certolizumab pegol; PNR, primary non response to anti-TNF
F agent; IL, interleukin; ICOS, inducible co-stimulator; LPMC, lamina propria mononuclear cells; mAb,
of Gastroenterology, Hôpital Saint-Louis, 1, avenue Claude Vellefaux, 75010, Paris, France. Tel.: +33 1
.aphp.fr (M. Allez).
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induction of TNF-independent inflammatory pathways and phenomena of paradoxical inflam-
mation are discussed.
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factor alpha (TNFα) and its available antagonists is essential
in order to delineate mechanisms for anti-TNF failures. In
this section, we review and discuss the current knowledge
regarding possible mechanisms leading to failures of anti-
TNF antibodies in the context of their effects at the cellular
level, TNF-receptor mediated activities, transmembrane
TNF-mediated activities, and the effect of TNFα and anti-
TNF agents on different cell types and tissues.1. Biology of TNFα in IBD (Table 1)
1.1. Biological activity of TNFa
TNFα is generated as a 26-kD transmembrane Type II
polypeptide precursor (tmTNF) which is expressed on
activated macrophages, T-lymphocytes, natural killer cells
and to a lesser extent on non-immune cells such as
endothelial cells, smooth muscle cells, keratinocytes and
neurons.1-3 Cleavage of tmTNF by TNFα converting enzyme
(TACE) releases soluble-TNFα (sTNF).4
TNFα exerts its effects both as a transmembrane protein
(tmTNF) and as soluble homotrimeric cytokine (sTNF)
through binding to its p55TNFR (TNFR1) and p75TNFR
(TNFR2) receptors.5 The TNF receptors diverge in their
cellular expression and despite the fact they share structural
homology in their extracellular TNF-binding domains, they
induce different cytoplasmic signaling pathways.6The pleiotropic effects of TNFα may be explained by the
distinct effects of sTNF and tmTNF and by signaling through
the different receptors. This signaling is affected by the
balance between tmTNF and sTNF, cell type, cellular
activation status, the stimulus eliciting TNFα production,
TACE activity, and expression of endogenous TACE inhibitors
leading to divergent TNF-mediated effects on cellular
viability.
Due to intracellular signaling motifs, tmTNF also serves as
a cell surface receptor and allows for “reverse” signaling in
TNFα producing cells,7 a fact highly relevant for understand-
ing the effects of anti-TNF agents.
The complexity and plasticity of the TNFα mechanisms of
action allows for a number of possibilities to explain primary
and secondary anti-TNF therapy failure (primary non
response (PNR) and loss of response (LOR)). Further insight
into relevant physiological mechanisms that play a role in
different disease states and the effect of the different anti-
TNF agents on these pathways will improve our understand-
ing of events that lead to loss of therapeutic response.
1.2. TNFR mediated activities at the cellular level
The two TNFRs are ubiquitously expressed and display
structurally similar extracellular domains but signal through
distinct intracellular regions. TNFR1 contains a death domain
while TNFR2 does not.8
TNFRs are initially synthesized as membrane-anchored
proteins which are cleaved by proteolysis, forming soluble
Table 1 Biology of TNF.
Key messages
1) TNFα is primarily synthesized as a type II transmembrane
molecule, which is further processed by the TNFα
converting
enzyme (TACE or ADAM17).
2) TNFα exerts its effects both as a transmembrane protein
(tmTNF) and as soluble homotrimeric cytokine (sTNF)
through binding to its p55TNFR (TNFR1) and p75TNFR
(TNFR2) receptors.
3) sTNF binds with high affinity to TNFR1, which contains a
death-domain–mediating apoptosis induction.
4) TmTNF appears to preferentially activate TNFR2 leading to
the recruitment of TNF receptor-associated factors (TRAF1
and TRAF2), which may subsequently activate NFk-B and
protect from caspase-8 mediated apoptosis induction.
5) Besides acting on effector cells (forward signaling), tmTNF
also functions as a cellular receptor on TNFα producing
cells (reverse signaling).
6) TNFα and TNF receptor activity are tightly negatively
regulated by mechanisms such as downregulation of TNF
production, shedding of transmembrane TNF and TNFR,
internalisation of TNF ligand–receptor complex, or reverse
signaling of tmTNF.
Questions to address in the future
1) What is the relevance of the different signaling pathways
in the context of the intestinal immune system, in both
inflamed and non inflamed states?
2) What is the significance of these pathways in the different
intestinal cell types and how do they affect each other?
369Biological roles and effects of TNF and TNF antagonistsmolecules capable of binding the TNFα ligand. Soluble TNFRs
are constitutively released to the circulation9 and their
levels increase in the course of various disease states10 and
following TNFα stimulation.11 In cell culture systems, soluble
receptors are rapidly produced in response to various stimuli
such as TNFα,12 LPS,13 PMA, IL-10 and after T cell and
neutrophil activation.14 Receptor shedding followed by
decrease in their cell surface density may serve to
desensitize cells to the TNFα stimulation. Additionally, the
pool of soluble forms could function as physiological
attenuators of the TNFα activity by competing for the
ligand. On the other hand, it has been proposed that soluble
receptors can stabilize and preserve circulating soluble TNFα
and thus function as TNFα agonists.15
It is generally admitted that TNFR1mediatesmost of TNFα
biological effects. Studies in TNFR1-knockout mice suggest
that it is the major mediator of TNFα toxicity and neutrophil
and endothelial activation.16 Signaling by the TNFRs is
mediated by binding of trimeric TNFα molecules to three
monomeric subunits of the receptor. Receptor aggregation
activates a downstream receptor-associated effect, or
facilitates recruitment of downstream factors to the receptor
complex, which then transduces signals through intracellular
signaling molecules. The cytoplasmic domains of the TNFR
are of modest length and function as docking sites for
signaling molecules. The various TNFα activities and their
coordinated induction are likely mediated by the heteroge-neity of the intracellular functional domains of TNFR1 and
adaptor proteins.
Three intracellular TNFR1 functional domains including
the C-terminal death domain, neutral sphingomyelase and
acidic sphingomyelase activating domains mediate down-
stream signaling events of the activated TNFR1 complex.17-19
Signaling occurs through two principal classes of cytoplasmic
adaptor proteins: TNF-associated factor (TRAF) and TNFR-
associated death domain (TRADD). How the receptor ligand
complex activates downstream signaling is not completely
understood. The precise pathways for activation of down-
stream caspases, AP-1, NFκB, and other intracellular
responses involve a variety of kinases, including IκB,
P38MAPK, JNK, sphingosine kinase, sphingolipase, phospho-
lipase, and other specialized signaling proteins.20-22 A
number of drug design studies are in progress based on the
fact that TNFα exerts its effects through TNFα/TNFR complex
formation.23
Almost all of the signaling mentioned above has been
described and focused on TNFR1, which was extensively
investigated in an attempt to understand the control of cell
death mechanisms as a possible therapeutic intervention.5
The association of TNFR1 with TRADD/FADD occurs through
the death domain which exists on TNFR1, but not on TNFR2,
and recruits a series of downstream signaling events
associated with cell death.24-27
TNFR2 activation by TNFα differs from TNFR1 activation.5
Once activated, TNFR2 is readily cleaved by metallopro-
teases into a soluble shed form which is still capable of TNFα
binding.28 The role of TNFR2 in cellular responses is not fully
understood. Activation of TNFR2 in some cells (mainly T-cells
and thymocytes) has been shown to induce proliferation, but
it was also shown to regulate TNFα induced apoptosis.22
TNFR2 does not contain a death domain motif but still
recruits adaptor proteins. It is thought to directly signal for
apoptosis.29 It has also been proposed that TNFR2 signal
through a so-called ‘ligand-passing’ mechanism. Indeed,
TNFR2 binding to TNFα may increase its concentration in the
vicinity of TNFR1 receptors. More precisely, TNFR1 may
accept the TNF ligand from TNFR2, then inducing an
apoptotic signal.30 Others have additionally shown that
TNFR2 signals for cell death through its cytoplasmic domain
to induce endogenous mTNF expression, which then signals
for apoptosis on itself through its own expressed TNFR1.311.3. Transmembrane tumor-necrosis factor alpha
(tmTNF)
Binding of sTNF to TNFRI was long-time considered as the
principal mechanism of TNFα induced pro-inflammatory
action. However, increasing evidence underlines a sTNF-
independent and biological relevant role of tmTNF and TNF-
RII mediated signaling in chronic inflammation.32 TmTNF was
shown to induce colitis and arthritis in the absence of
sTNF.33,34
Besides tmTNF “forward signaling” via binding of TNF-
receptors on effector cells, tmTNF also functions as a cellular
receptor on TNFα producing cells by “reverse signaling”.
Reverse signaling through tmTNF in monocytes leads to
subsequent phosphorylation of the cytoplasmic tail, binding
of casein kinase I, elevation of intracellular calcium and
Table 2 Mechanisms of action of anti-TNF mAbs.
Key messages
1) All anti-TNF antibodies have a high affinity for sTNF.
2) Binding of anti-TNF antibodies to tmTNF can block tmTNF
interaction with TNF-receptors, neutralize forward signaling
via TNF-receptors and/or activate the reverse signaling
pathway.
3) IFX, ADA and – with conflicting results – etanercept were
shown to induce apoptosis in peripheral blood monocytes,
370 Y. Chowers et al.signaling through p38 — a mitogen-activated protein (MAP-)
kinase extracellular signal-regulated kinase pathway.7,35,36
The phosphorylation of human tmTNF by antibody-treatment
seems restricted to serine residues of its cytoplasmic
domain.37 A 10 kDa proteolytic fragment of the intracellular
portion of tmTNF was observed as a putative nuclear
localization signal.38 Recent evidence in dendritic cells
suggests that signal peptide peptidase-like proteases (SPPLa
and SPPLb) cleave the intramembrane site of tmTNF, thereby
initializing reverse signaling.39leukemic TPH-1 cells and lamina propria T-cells by reverse
signaling, whereas CZP did not.
4) Etanercept and CZP bind to a single tmTNF trimer, while
IFX and ADA are able to bind two tmTNF trimers at the same
time, thereby having the potential to crosslink neighbored
tmTNF.
5) Binding of anti-TNF antibodies to tmTNF induces
suppression of pro-inflammatory cytokines, cell activation
and upregulation of adhesion molecules in different tmTNF
transfected cell lines, all indicating a downregulation of
inflammation.
6) Complement dependent cytotoxicity and antibody
dependent cytotoxicity of tmTNF bearing cells after
stimulation with anti-TNF antibodies was shown.
Questions to address in the future
1) What is the effect of the different anti-TNF agents on
expression and function of these signaling pathways and
what does it teach us regarding their mechanism of action?
2) What changes in expression and signaling occur in the
intestinal mucosa during the course of and following loss of
response to anti-TNF therapy?
3) How do other drugs used in IBD therapy affect TNF
signaling and the therapeutic effects of anti-TNF agents?2. Mechanismof actionof anti-TNFmAbs (Table2)
Binding of anti-TNF antibodies to tmTNF can block tmTNF
interaction with TNF-receptors and neutralize forward
signaling via TNF-receptors and/or activate the reverse
signaling pathway. Infliximab (IFX), adalimumab (ADA),
etanercept and certolizumab pegol (CZP) were shown to
bind to tmTNF in transfected human cell lines and induce
reverse signaling.40-45 IFX, ADA and – with conflicting results
– etanercept, were shown to induce apoptosis in peripheral
blood monocytes, leukemic TPH-1 cells and lamina propria T-
cells by reverse signaling, whereas CZP did not.42,43,46-49
IFX, ADA and etanercept were shown to equally neutralize
sTNF,43 but surprisingly, etanercept failed to show clinical
effectiveness in granulomatous diseases such as Wegener's
granulomatosis,50 pulmonary sarcoidosis51 and Crohn's dis-
ease,52 indicating that there is an additional anti-inflamma-
tory action of anti-TNF-antagonists besides neutralization of
sTNF. Although differences in ligand binding, crosslinking
and induction of complement dependent and antibody
dependent cytotoxicity41,53 may explain these biological
differences, the exact reason why etanercept treatment
fails in granulomatous disease remains unclear.
Crosslinking seems to be dispensable for reverse signaling,
but may explain the different biological potency of the drugs
depending on the amount tmTNF expression on cell surfaces
and micro environmental conditions at site of inflamma-
tion.41 IFX and ADA, both binding two tmTNF trimers
simultaneously, have the potential to crosslink neighboring
tmTNF molecules.40
Binding of anti-TNF antibodies to tmTNF was shown to
suppress pro-inflammatory cytokines, and cell activation as
well as downregulate adhesion molecules in different tmTNF
transfected cell lines.54 In line with this hypothesis,
resistance to endotoxin mediated cytokine production by
reverse signaling has been observed in monocytic cells
following treatment with anti-TNF antibodies.7,43
Complement dependent cytotoxicity and antibody de-
pendent cytotoxicity of tmTNF bearing cells after stimula-
tion with anti-TNF antibodies was demonstrated.49,53 IFX and
ADA exerted almost equal complement dependent activities
in tmTNF transfected cells, while Etanercept was consider-
ably less effective in this regard.41,44,53 Nevertheless, these
observations were not confirmed in normal activated human
peripheral blood mononuclear cells.45
It should be noted that most of the experimental data on
tmTNF signaling were obtained using transfected in vitro
systems with cells expressing abnormally high amounts of
tmTNF in the absence of TNF-RI/II and sTNF. In vivo tmTNFmay
act simultaneously in concert with other agonistic andantagonistic signaling pathways, turning the TNFα signaling
pathways into a highly complex system. Further insight into the
different binding properties of TNFα antagonists, the intra- and
extracellular signalingmechanisms and adaptations are needed
in order to better understand the reasons of loss of response.
3. Hypotheses regarding anti-TNF failures (Table 3)
3.1. Cellular mechanisms for loss of response to
anti-TNF
TNFα is central to cellular inflammatory responses. As such,
it is not surprising that there are several ways that cells
tightly regulate TNFα and TNFα receptor activity. When
considering how this occurs, it is important to discuss three
different events. First, signaling pathways are complex and
incompletely understood. For example, sTNF preferentially
binds TNFR1 and tmTNF preferentially binds TNFR2,55 but in
reality the precise roles of each agonist and receptor are
uncertain. Second, responses will vary depending on cellular
activation and cell type. Third, our understanding is largely
derived from experiments in single cell systems, which may
not represent the more complex in vivo state.
Table 3 Hypotheses regarding anti-TNF failures.
Key messages
1) Paradoxical inflammatory events can occur in IMID patients
treated with anti-TNF agents.
2) Paradoxical inflammation can occur in the intestine and
thus contribute to loss of response.
3) Little is known about the effect of anti-TNF agents on
other inflammatory pathways.
Questions to address in the future
1) What are the effects of anti-TNF agents on “other”
inflammatory pathways in IBD?
2) Are there inflammatory pathways in IBD which are TNFα
independent?
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Lack of response to anti-TNF agents could be due to the
importance of other inflammatory pathways which are
potentially TNFα-independent. Another possibility is that
anti-TNF agents may promote some alternative inflammato-
ry pathways. This could explain the observation of paradox-
ical inflammatory events in immune-mediated inflammatory
disorders (IMID) patients treated with anti-TNF agents. This
section is divided in 3 parts: first, we review data on cases of
paradoxical inflammation, second, we propose some poten-
tial explanations for the induction of inflammation through
TNFα blockade, and third, we review other inflammatory
pathways which are potentially TNF-independent.3) Can loss of response to anti-TNF agents be explained by the
induction/promotion of other inflammatory pathways
which are normally downregulated by TNF?
4) Could the identification of these pathways in anti-TNF
failures help us to perform a rational drug switch or select
the best drug combination?3.3. Paradoxical inflammation
Paradoxical inflammatory events have been described in
patients with diverse IMID treated with anti-TNF agents. It
can be defined by the development of inflammatory lesions
in IMID patients after initiation of treatment with anti-TNF
agents, normally used to treat them. IBD patients treated
with anti-TNF agents can paradoxically experience the onset
of other IMID, particularly skin inflammatory lesions resem-
bling psoriasis. These anti-TNF-induced paradoxical inflam-
matory lesions observed in IMID suggest that anti-TNF could
promote inflammation in some patients. We first review
clinical data regarding these paradoxical inflammatory
events, and then discuss the potential role of anti-TNF in
other inflammatory pathways.
Inflammatory skin disorders occurring under anti-TNF
therapy are an emerging problem.56 A recent study has
shown that the incidence rate of new onset psoriasis was high
in rheumatoid arthritis patients treated with anti-TNF
therapy, while no cases of new onset psoriasis were
identified in a large cohort of patients treated with
traditional therapy.57 Interestingly, the risk of developing
psoriasis varied with the anti-TNF agent. In a recent case
series describing the experience with use of a third anti-TNF
agent in CD, psoriasis-like lesions occurred under the first
anti-TNF treatment in 3 patients, relapsing with the second
and third line.58 One patient developed de novo psoriasis
with the third anti-TNF. In all cases, improvement was
observed when anti-TNF was stopped; but psoriasis relapsed
in all cases with use of the next anti-TNF agent. In most cases
(4/5), anti-TNF had to be stopped, but one patient used
topical treatment and continued the anti-TNF.
New onset of IBD in ankylosing spondylitis patients
treated with anti-TNF has been described, but is infrequent
and may be only due to the association between both
diseases.59 New onset of CD has been reported in a series of
patients with juvenile idiopathic arthritis treated with anti-
TNF agents.60 In a retrospective study on paradoxical adverse
events in 296 patients with spondylarthropathies treated
with anti-TNF agents, 4 cases with de novo intestinal
manifestations under etanercept or IFX were reported,
corresponding to respective rates of 1 and 0.3 per 100
patient-years.61 In the same series, there were 5 cases of de
novo psoriasis and 3 cases of acute anterior uveitis. None of
these events appeared to be specific of the different anti-
TNF agents.These events of paradoxical inflammation in IMID patients
treated with anti-TNF agents clearly suggest that there are
TNF-independent inflammatory pathways relevant to human
disease, and even suggest that these pathways could be
induced or promoted by the anti-TNF agents themselves.3.4. Induction of other pro-inflammatory pathways
through TNF blockade
The mechanisms responsible for the appearance of “para-
doxical inflammation” in some IBD patients treated with
anti-TNF are mostly unknown. Some important inflammatory
pathways described in CD may be independent of TNFα, and
some pro-inflammatory pathways could even be upregulated
by TNFα blockade.
3.4.1. IL17/IL23
In a recently published paper, Notley and co-workers
analyzed the effect of anti-TNF therapy on Th1 and TH17
cells.62 TNF blockade in mice with collagen-induced arthri-
tis, using either TNFR-Fc fusion protein or an anti-TNF
monoclonal antibody, not only resulted in the expected
improvement in joint inflammation, but also in the presence
of expanded populations of Th1 and Th17 cells in the
periphery. The pathogenic capacity of these cells was further
confirmed using adoptive transfer models. The authors
provided a plausible explanation to reconcile the anti-
inflammatory effect observed in the mice joints and the
finding of expanded Th1 and Th17 cells through additional
experiments in which they demonstrated that while TNFα
blockade increased the numbers of Th1 and Th17 cells in
lymph nodes, it simultaneously inhibited their accumulation
in the joints.62
Another study used the CD45RB high T-cell transfer model
of colitis to demonstrate that in addition to inducing a
marked improvement in colonic inflammation, anti-TNF
therapy, downregulated IL2, IFNγ gamma and TNFα
372 Y. Chowers et al.secretion by lamina propria CD4+ T cells and also resulted in
a significantly decreased expression of IL23p19 and IL17 in
the inflamed colon.63
Probably more relevant for human IBD are the studies
conducted in rheumatoid arthritis (RA) patients. In one of
these studies, Kageyama et al. found that treatment of RA
with IFX, but not with methotrexate, resulted in a significant
reduction in serum IL-23 levels, with no changes in serum
IL17 levels.64 The same group previously reported that
infliximab therapy in RA patients caused a marked reduction
in serum IL-15 levels, whereas it has no effect on serum IL16,
IL17 or GM-CSF levels.65
The notion that anti-TNF therapy is able to down-regulate
other well-known pro-inflammatory pathways was further
supported by Popa and co-workers, using a different
experimental approach. These investigators performed
cultures of whole blood obtained from RA patients under
ADA or etanercept therapy and from healthy volunteers and
demonstrated that upon exposure to a range of bacterial
stimuli, including heat-killed Salmonella typhimurium, or
Staphylococcus aureus, as well as with Salmonella typhimur-
ium LPS, lower production of IL1β and TNFα and a trend
towards lower IL6 and IFNγ production is found in RA
patients, compared to healthy subjects.66
Taken together it appears that a growing body of evidence
suggests that anti-TNF therapy has a broad impact on the
immune system which exceeds the blockade of TNFα itself.
Some studies suggest that the decrease in Th1 and Th17 cells
downregulates several pro-inflammatory cytokines that
ultimately contribute to the beneficial effect of this therapy.
Even if this has not been specifically addressed, all the
cited evidence supports the hypothesis that the appearance
of anti-TNF induced paradoxical inflammation is mediated by
consistent upregulation of other pro-inflammatory path-
ways. Paradoxical inflammation, which occurs in a minority
of IBD patients treated with TNFα antagonists, could be
associated with the up regulation of some inflammatory
cytokines. The observation that Th1 and Th17 cells may
increase in organs other than those that are inflamed and
target of anti-inflammatory therapy supports this hypothe-
sis. Studies aimed at thoroughly characterizing cell popula-
tion and cytokine expression in mucosal, circulating
inflammatory cells and cells in organs affected with IMID in
these patients should provide a final answer to this question.3.4.2. IFN alpha
TNFα downregulates the production of IFNα by plasma-
cytoid dendritic cells, and vice versa.67 Anti-TNF agents
increase the production of IFNα.68 Consequently, a pro-
longed blockade of TNFα using anti-TNF agents could by
itself promote IFNα production. Such situation mimics
infections where there is increased production of IFNα.
IFNα has a potential role in the pathogenesis of psoriasis,
where it is involved in induction of the chemokine receptor
CXCR3 on T cells, maturation and stimulation of myeloid
dendritic cells, and expression of pathogenic T cells via IL-15
production in the skin. Furthermore, an increased expression
of IFNα has been demonstrated in psoriatic lesions of
patients treated with anti-TNF agents. Thus, a side effect
of TNFα blockade may be over expression of IFNα resulting in
IFNα-driven inflammation.3.5. Other pathways involved in
intestinal inflammation
A number of experimental systems show that altered
regulation of intestinal T cell function can result in chronic
intestinal inflammation which may be due either to impaired
regulatory T cell activity or excessive effector T cell
function.69 Several receptors expressed on effector T cells
have been recently described in IBD. Some of these
inflammatory pathways could be TNF-independent.3.5.1. NKG2D pathway
NKG2D is an activating receptor preferentially expressed
on CD8+ T cells, γδ T cells and NK cells. NKG2D ligands are
expressed on the intestinal epithelium, and most of them
appear up regulated in IBD. A subset of mucosal CD4+ T cells
characterized by NKG2D expression on their surface and
mediating cytotoxic and inflammatory response has been
described in CD.70 These CD4+ effector T cells expand in the
mucosa and the periphery of CD patients but not in UC
patients. CD4+ NKG2D+ T cells have been recently described
in the transfer-induced colitis in SCID mice.71,72 NKG2D may
play a role in the early stage of colitis in this model, since
early administration of anti-NKG2D mAb attenuated the
development of colitis. The effect of anti-TNF therapies on
the NKG2D pathway has not been studied yet.3.5.2. TNF/TNFR superfamily members
Several co-stimulatory molecules, belonging to the TNF
superfamily, amplify the immune response and can promote
inflammation.73 These pathways play a critical role in
mucosal inflammation and experimental colitis that could
be TNF-independent. Members of the TNF superfamily that
may be involved in these inflammatory processes include
CD40 (TNFRSF5)/CD40L (CD154), TL1A (TNFSF15)/DR3
(TNFRSF25), OX40 ligand (CD252 and TNFSF4) and OX40
(CD134 and TNFRSF4), 4-1BB ligand (TNFSF9) and 4-1BB
(CD137 and TNFRSF9), ICOS (CD278)/B7RP-1 (CD275), CD70
(TNFSF7) and CD27 (TNFRSF7), BTNL2.
CD40, expressed by lamina propria B lymphocytes and non-
immune cells, such as human intestinal fibroblasts (HIFs) and
human intestinal microvascular endothelial cells (HIMECs),
interacts with the CD40 ligand on T cells and activated
platelets (Danese 2004). These interactions are implicated in
the pathogenesis of IBD through multiple effects on humoral,
cell-mediated immunity and inflammation.74 The expression
of both CD40 and CD40L is increased in the inflamed human
intestine, whereas blockade of the CD40–CD40L pathway can
prevent or improve colitis in several animal models of
IBD.75,76 Uhlig et al. have shown that injection of an agonistic
CD40 mAb to T and B cell-deficient mice was sufficient to
induce a pathogenic systemic and intestinal innate inflam-
matory response that was functionally dependent on TNFα
and INFγ as well as IL-12 p40 and IL-23 p40 secretion. This
CD40-induced colitis depended on IL-23 p19 secretion,
whereas IL-12 p35 secretion controlled wasting disease and
serum cytokine production but not mucosal immunopathol-
ogy. Intestinal inflammation was associated with IL-23 (p19)
mRNA-producing intestinal dendritic cells and IL-17A mRNA
within the intestine.77
373Biological roles and effects of TNF and TNF antagonistsSimilarly OX40+ cells and OX40L+ gut endothelial cells are
increased in IBD patients compared to patients with irritable
bowel syndrome.78 CD252 (OX40L) expression in dendritic cells
in draining mesenteric lymph node may drive experimental
colitis in the adoptive transfer model.79 Administration of
OX40-IgG fusion protein to mice with ongoing colitis (but not
the OX40 ligand-IgG) ameliorated disease in hapten-induced
colitis or IL-2 knockout mice with spontaneous colitis.80 The
therapeutic effect of OX40-Ig fusion protein in experimental
colitis could be related to enhancement of IL-10 production.81
Both inducible co-stimulator (ICOS)-expressing CD4+ lamina
propria mononuclear cells (LPMC) and B7h-expressing B cells,
macrophages, and epithelial cells are significantly increased in
the inflamed mucosa of IBD patients.82 Anti-CD3/ICOS-
stimulated-LPMC from UC secreted significantly increased
amounts of IL-5. In contrast, anti-CD3/ICOS-stimulated-LPMC
from CD secreted significantly increased amounts of IFN-γ in
the presenceof IL-12.82 Although ICOS/B7RP-1 interactions are
not required for the development of colitis, treatment with
anti-ICOS mAb can prevent and reverse experimental intesti-
nal inflammation by inducing apoptosis of ICOS-expressing T
lymphocytes.83 In contrast, de Jong et al., showed that
blocking ICOS on the surface of CD28-deficient T(h)1 cells
abrogated development of colitis, whereas blocking CD28 or
ICOS alone had little to no effect on disease induction.84
Recent data suggest that anti-CTLA4 administration in mice
induced amelioration of colitis which correlated with Indolea-
mine-2,3-dioxygenase (IDO) expression and infiltration of
ICOShigh Foxp3+ T cells in the intestine.85
The role of TL1A–DR3 pathway in infectious and inflam-
matory diseases is beginning to be elucidated. Both TL1A and
DR3 expressions is increased in human and murine IBD.86,87
TL1A enhances cytokine production (Th1 and Th17) by
cytokine-stimulated T cells, whereas anti-TL1A Ab adminis-
tration prevents and ameliorates experimental colitis.88-90
The 4-1BBL and 4-1BB as well as the CD70/CD27 pathways
may be involved in IBD pathogenesis as suggested by the
observation that anti-4-1BB and anti-CD70 Ab administration
improves experimental colitis.91-93 Programmed death-1
(PD-1), interacts with B7-H1 (PD-L1) and B7-dendritic cells
(B7-DC; PD-L2) and provides a negative signal that is
essential for immune homeostasis. Expression of PD-1 on T
cells and of B7-H1 on T, B, and macrophage/DCs is increased
in inflamed colon from both IBD patients and colitic mice.
Furthermore, administration of anti-B7-H1, but not anti-B7-
DC, mAb after transfer of CD4+CD45RBhigh T cells suppressed
wasting disease with colitis.94
The interaction between the TNF family member LIGHT
and the TNF family receptor herpes virus entry mediator
(HVEM or TNFRSF14) co-stimulates T cells and promotes
inflammation.95 LIGHT also binds the lymphotoxin beta
receptor.96 These molecules play an important role in
regulating immunity, particularly in the intestinal mucosa.97
LIGHT-transgenic mice exhibit abnormalities in both lym-
phoid tissue architecture and the distribution of lymphocyte
subsets and develop intestinal inflammation.95 HVEM can
also act as a ligand for immunoglobulin family molecules,
including B- and T-lymphocyte attenuator (BTLA), which
suppresses immune responses. Recent data, however,
suggest an anti-inflammatory role for HVEM and the
importance of HVEM expression by innate immune cells in
preventing intestinal inflammation.98 Butyrophilin-like 2(BTNL2) is a butyrophilin family member with homology to
the B7 co-stimulatory molecules. BTNL2 is over expressed
during both the asymptomatic and symptomatic phase of the
MDR1a knockout model of spontaneous colitis. BTNL2-Fc
reduces proliferation and cytokine production from T cells
activated by anti-CD3 and B7-related protein 1, suggesting a
role for BTNL2 as a negative co-stimulatory molecule.99
4. Conclusion
TNFα blockade can lead to shifts of inflammatory and
regulatory cell populations and differentially regulate cells
secreting specific cytokines. Under anti-TNFα therapies most
pro-inflammatory cytokines are downregulated although
some pro-inflammatory cytokines pathways may be upregu-
lated. Additional inflammatory pathways than TNFα have
indeed been shown to play a pivotal role in intestinal
inflammation and future studies should address the role of
these non-TNFα mediated pathways in loss of response to
TNFα blockade and development of paradoxical inflamma-
tions in other organs.
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